Scientific Opinion on the substantiation of health claims related to Lactobacillus johnsonii NCC 533 (La1) (CNCM I‐1225) and improving immune defence against pathogenic gastro‐intestinal microorganisms (ID 896), and protection of the skin from UV‐induced damage (ID 900) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

摘要

This opinion addresses the scientific substantiation of health claims in relation to Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) and improving immune defence against pathogenic gastro-intestinal microorganisms, and protection of the skin from UV-induced damage. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claim is Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225). The Panel considers that Lactobacillus johnsonii NCC 533 (La1) (CNCM I-1225) is sufficiently characterised. Improving immune defence against pathogenic gastro-intestinal microorganisms The claimed effect is “natural defence/immune system”. The target population is assumed to be the general population. In the context of the clarifications from Member States and the references provided, the Panel assumes that the claimed effect refers to improving immune defence against 1 On request from the European Commission, Question No EFSA-Q-2008-1683, EFSA-Q-2008-1687, adopted on 25 March 2011. Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus L?vik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuh?user-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.